Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
about
Prodrug Strategies for PaclitaxelTargeted Delivery Systems for Molecular Therapy in Skeletal DisordersDual-targeting delivery system for bone cancer: synthesis and preliminary biological evaluation.Targeting polymer therapeutics to bone.Polymeric conjugates for drug deliveryDoxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.Biological rationale for the design of polymeric anti-cancer nanomedicines.Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats.Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model.Materials innovation for co-delivery of diverse therapeutic cargos.Nanomedicine: a pharma perspective.The critical role of bisphosphonates to target bone cancer metastasis: an overview.Role of polymer-drug conjugates in organ-specific delivery systems.Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering.Inhibition of fibrous dysplasia via blocking Gsα with suramin sodium loaded with an alendronate-conjugated polymeric drug delivery system.Biodegradable polymers for targeted delivery of anti-cancer drugs.Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer.NF-κB as a Therapeutic Target in Inflammatory-Associated Bone Diseases.Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.Bone-targeting poly(ethylene sodium phosphate).Integrin-targeted nano-sized polymeric systems for paclitaxel conjugation: a comparative study.Bisphosphonate conjugation for bone specific drug targeting.
P2860
Q26745997-4F4E0A0C-D539-4D80-8616-8B20B7EF00D5Q26752158-0F543333-D4DE-421F-B486-8B798A3A484AQ34416829-7D510440-0821-4EAE-AC44-528688AA551FQ35951743-B47A30FD-A1B2-49CD-802F-27D24ADCB22BQ36029175-4A0EC89E-3CCC-4F72-BB70-877CE88FF42EQ36106734-24792953-E064-4F5B-B44A-7B7B2E8EF578Q36160333-753B33A8-EC88-401D-94A4-39ED6DD601F4Q36940281-1BD70EA5-5E48-494E-8B46-4F8AE1F50734Q37476433-AF3CC191-1498-4241-B4C6-7A1FB7881D80Q38211033-D79849BD-CEA0-4F09-B0BC-8649277C5F89Q38246663-6DBCFC67-BB8A-45C2-81C8-30BFBDCDA9FDQ38247428-5DF668D3-B68E-4D3C-900C-52951BC1C6CCQ38365556-18A78CAA-B9C7-405C-B395-A895CB57FADEQ38367669-255A90D3-FBE5-4FCE-8B1B-D10B33987CB1Q38770818-06FC5629-A327-4543-BF9D-C0DAEAA4B487Q38777436-6F08E8E9-D5F9-474B-90B3-255CE3577ED2Q39138688-F783F59A-3C26-45CA-AA50-B72489F9B06AQ39142554-A3571E18-DDCC-4474-ABAE-4AF3409BF9DFQ46924536-BC074345-7DFE-49A9-8536-A66C4ED0E3A7Q47304447-C05DFB39-3A59-4F4D-B4AB-0E24BE0EB73CQ47959735-21E8DF90-32DD-471A-9671-90DE56D39F74Q55515922-7C0F5197-2348-466C-AE72-A886E194B23E
P2860
Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Antiangiogenic antitumor activ ...... r bone metastasis mouse model.
@en
Antiangiogenic antitumor activ ...... r bone metastasis mouse model.
@nl
type
label
Antiangiogenic antitumor activ ...... r bone metastasis mouse model.
@en
Antiangiogenic antitumor activ ...... r bone metastasis mouse model.
@nl
prefLabel
Antiangiogenic antitumor activ ...... r bone metastasis mouse model.
@en
Antiangiogenic antitumor activ ...... r bone metastasis mouse model.
@nl
P2093
P356
P1476
Antiangiogenic antitumor activ ...... r bone metastasis mouse model.
@en
P2093
Anat Eldar-Boock
Dina Polyak
Ehud Segal
Keren Miller
Liat Benayoun
Yuval Shaked
P304
P356
10.1021/MP200083N
P407
P577
2011-05-17T00:00:00Z